AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting

86

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA® (olaparib) and IMFINZI® (durvalumab) at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 to June 4, 2019. In all, the Company will present 93 abstracts spanning multiple tumor types, including 12 oral presentations with one plenary session and four late-breakers. Highlight http://www.businesswire.com/news/home/20190516005389/en/AstraZeneca-Continues-Redefine-Cancer-Treatment-2019-ASCO/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==